Skip to content

Paed Epilepsy – Improve growth and bone mass

Evidence Summary
• In a cross-sectional study of 27 children with epilepsy who have been treated with valproate and/or lamotrigine for 2 or more years, the inactive group had significantly lower body height percentile and lower total bone mineral density (1).

Quality of Evidence
• B – moderate/low quality
Strength of Recommendation
• Grade 2 – weak recommendation

• Inactivity led to significantly lower body height percentile and total BMD in patients on long term valproate and/or lamotrigine in one cross-sectional study. Physical activity could be recommended to mitigate this however more studies are required to build up clinical evidence. Current evidence is limited relating specifically to children with epilepsy.


  1. Guo et al; Long-term Valproate and Lamotrigine Treatment May be a Marker for Reduced Growth and Bone Mass in Children with Epilepsy. Epilepsia 2001; 42(9): 1141-1147


Public Health England and partners would like to hear from healthcare professionals using the Moving Medicine website. Please follow the link below to participate in our survey. It takes around 5 minutes to complete.

The survey opens in a separate window, and is hosted by Ipsos MORI, an independent research organisation.

If you’ve previously completed this survey, thank you, please close this message.

Click here to take part